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Abstract
Background: Principal Treatment Centres (PTC) were established to provide age-appropriate care as well as clinical
expertise for children and young people with cancer. However, little is known about the effects of specialist treatment
centres on survival outcomes especially for teenagers and young adults. This population-based study aimed to
describe access to PTC and the associated trends in survival for 0–24 year olds accounting for stage of disease at
presentation and treatment.
Methods: Patients diagnosed from 1998–2009 aged 0–24 years were extracted from the Yorkshire Specialist Register of
Cancer in Children and Young People, including information on all treating hospitals, followed-up until 31st December
2014. The six commonest cancer types were included: leukaemia (n = 684), lymphoma (n= 558), CNS tumours (n = 547),
germ cell tumours (n = 364), soft tissue sarcomas (n = 171) and bone tumours (n = 163). Treatment was categorised into
three groups: ‘all’, ‘some’ or ‘no’ treatment received at a PTC. Treatment at PTC was examined by diagnostic group and
patient characteristics. Overall survival was modelled using Cox regression adjusting for case-mix including stage,
treatment and other socio-demographic and clinical characteristics.
Results: Overall 72% of patients received all their treatment at PTC whilst 13% had no treatment at PTC. This differed by
diagnostic group and age at diagnosis. Leukaemia patients who received no treatment at PTC had an increased
risk of death which was partially explained by differences in patient case-mix (adjusted Hazard Ratio (HR) = 1.
73 (95%CI 0.98–3.04)). Soft tissue sarcoma patients who had some or no treatment at PTC had better survival
outcomes, which remained after adjustment for patient case-mix (adjusted HR = 0.48 (95%CI 0.23–0.99)). There were no
significant differences in outcomes for other diagnostic groups (lymphoma, CNS tumours, bone tumours and germ cell
tumours). For leukaemia patients survival outcomes for low risk patients receiving no treatment at PTC were similar to
high risk patients who received all treatment at PTC, implying a benefit for care at the PTC.
Conclusion: This study demonstrates that for leukaemia patients receiving treatment at a PTC is associated with
improved survival that may compensate for a poorer prognosis presentation. However, further information on risk factors
is needed for all diagnostic groups in order to fully account for differences in patient case-mix.
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Background
Cancers in children and young people are rare, accounting
for approximately 1% of all cancers diagnosed in the UK,
however, cancer is one of the leading causes of death in
this age group [1]. The National Institute for Health and
Clinical Excellence Improving Outcomes Guidance (IOG)
for cancer in children and young people published in 2005
aimed to improve outcomes for this population by recom-
mending the provision of age-appropriate care and clinical
expertise [2]. Principal Treatment Centres (PTC) were
established, which operate within high volume cancer cen-
tres to provide specialist care for this group of patients.
There are currently 21 paediatric PTCs in the UK and
Ireland where the majority of children, aged 15 and under,
with cancer are treated [3]. For paediatric cancers there is
evidence that higher volume hospitals and specialist hos-
pitals provide care with better outcomes, however many
studies included in a recent systematic review were unable
to account for stage of disease and other confounding fac-
tors such as age, sex, treatment and other patient demo-
graphics [4].
Services for teenagers and young adults (TYA) have
developed since 2005 and there are currently 25 desig-
nated TYA PTC in England [5, 6]. Some PTC include
units for both children and TYAs. Cancer patients aged
16 to 18 years are managed at a PTC and those aged 19
to 24 years are assessed at a PTC and given an informed
choice where they are treated [2]. Analysis of TYA hos-
pital admissions (aged 15–24) in England between 2001
and 2006 found that many TYA patients received little
or no inpatient treatment at TYA specialist centres [7].
However, little is known about the effects of specialist
treatment centres on survival for TYA.
The aims of this paper were to describe the patterns of
care for the population of children and young people with
cancer in Yorkshire between 1998 and 2009, therefore in-
cluding periods before and after the establishment of
PTCs for TYA, and assess the association with trends in
survival, accounting for clinical prognostic factors which
we are unique in being able to assess, notably stage and
treatment using data from a specialist cancer register.
Methods
Study population
Data were extracted from the Yorkshire Specialist Register
of Cancer in Children and Young People (YSRCCYP),
which is a population based database of children and
young people (0–29 years) diagnosed with cancer residing
in the Yorkshire and Humber region in England. The
primary source of ascertainment was hospital records via
the PTC with secondary sources including neuropathology
reports, hospital admissions and other regional and na-
tional cancer registries [8]. The database contains detailed
information on clinical prognostic factors including de-
tailed treatment and stage information.
Data on all registered neoplasms diagnosed in children
(0–14 years) and TYA (15–24 years) between 1998 and
2009 were extracted. Diagnoses were categorised into
histological groups according to the International Classifi-
cation of Childhood Cancer 3 (ICCC-3) [9]. We included
the six most common main diagnostic groups in this age
range: leukaemia, lymphoma, central nervous system
(CNS), malignant bone tumours, soft tissue sarcomas and
germ cell tumours corresponding to ICCC codes I, II, III
and VIII, IX and X, respectively. Biennial proactive follow-
up of cases was carried out to ascertain each individual’s
vital status, with a censoring date of 31st December 2014.
For each patient we identified all hospitals where they
received any treatment (surgery, radiotherapy or chemo-
therapy). Each hospital (whether in Yorkshire or outside)
was classified into one of two groups: PTC or non-PTC
based on designation for NHS quality reviews. Hospitals
were defined as a PTC if they were designated a PTC for
paediatric or TYA patients [3, 5]. Some of the PTCs may
not have been operating as a PTC over the entire study
period, however if a PTC started to operate during the
study period the centres would have had a high level of
clinical expertise for children and young people and
therefore we assigned centres as PTCs based on current
practice regardless of when the centre started operating.
In the Yorkshire region PTCs for children and TYA
are in Leeds and Sheffield; based on the study popula-
tion, in Leeds a minimum of 78 children and 57 TYA
were treated each year at the PTC and in Sheffield a
minimum of 35 children and 18 TYA were treated at the
PTC each year. The majority of our study population
were treated within the Yorkshire region at these PTCs,
however, patients may have been treated at other PTCs
throughout the UK, and these hospitals are listed in
Additional file 1: Table S1. Patients may also have re-
ceived treatment at other non-PTC hospitals in York-
shire or elsewhere in the UK and a total of 89 non-PTC
hospitals were included in the analysis with the average
volume of patients ranging from less than 1 patient per
year to 10 patients per year. An indicator was created to
identify if all treating hospitals for each patient were
PTC, if some treating hospitals were PTCs or if no treat-
ing hospitals were PTCs. The ‘some’ treatment at PTC
group included patients who had a mix of treatments at
PTC and non-PTC hospitals.
Stage at diagnosis was available for selected diagnostic
groups. White cell count was used as a proxy for stage for
leukaemia; lymphoma stage was assessed using the Ann
Arbor staging system; the Royal Marsden or TNM stage
was used for testicular germ cell tumours and FIGO stage
for ovarian germ cell tumours. We were unable to obtain
sufficient stage information for bone tumours and soft
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tissue sarcomas. CNS tumours were categorised ac-
cording to WHO grade. For each main diagnostic
group further subgroups according to the ICCC-3 were
extracted (see Additional file 2: Tables S2 and Additional
file 3: Tables S3). For bone tumours additional informa-
tion on the primary site was extracted based on topog-
raphy and coded as leg, arm, pelvis or ‘other’.
For each patient, treatment was recorded as three sep-
arate binary indicators in terms of receiving chemother-
apy, surgery or radiotherapy. A combined treatment
modality variable was created within each diagnostic
group. Treatment modalities with fewer than 30 patients
per group were grouped into an ‘Other’ treatment group,
whilst patients with no treatment recoded were included
as a separate category.
Other data items extracted included age at diagnosis,
year of diagnosis, sex, and relapse information. Ethnicity
was defined as South Asian or non-South Asian based
on the results from a name recognition software pro-
gram Onomap [10, 11] and individual patient record
linkage to hospital episode statistics data as described in
previous studies [8, 12]. The area based Townsend
deprivation index [13] was obtained from the patient’s
postcode at diagnosis.
Statistical analysis
The percentage of patients treated at PTC by patient
characteristics and diagnostic group were calculated.
Kaplan Meier plots were used to describe overall sur-
vival by level of treatment at PTC. Cox proportional haz-
ards models were used to model survival trends to
assess the association between level of treatment at PTC
and risk of death. Unadjusted and adjusted models were
fitted separately for each diagnostic group. The adjusted
model included diagnostic subgroup, age at diagnosis,
stage or grade (for leukaemia, lymphoma, CNS tumours
and germ cell tumours), treatment, relapse status, sex,
year of diagnosis, ethnicity, and deprivation. Models for
bone tumours also included primary site in the adjusted
model. For bone tumours and soft tissue sarcomas the
number of patients receiving some or no treatment at
PTC were small, therefore these categories were com-
bined. Predicted survival curves for selected groups of
patients were estimated from the adjusted Cox model.
Overall 2% of PTC information was missing. Levels of
missing data for stage and grade varied by diagnostic
group: white cell count was missing for 18% of cases,
lymphoma stage missing for 46%, CNS grade missing for
55% and germ cell tumour stage for 43%. For CNS tu-
mours with missing data, grade was assigned as low
grade (WHO Grade I and II) or high grade (WHO grade
III and IV) based on tumour morphology [14]. Not all
cases could be assigned a grade due to insufficient infor-
mation, however using this method we were able to
assign a grade to another 46% of all CNS tumours, redu-
cing missing grade status to 9%.
Missing PTC status, stage and grade were imputed
using multiple imputation models with chained equa-
tions [15] and implemented in Stata 14 using the ‘mi’
commands [16]. Each imputation model included all co-
variates listed previously as well as the Nelson-Aalen es-
timate for the cumulative hazard function and a death
indicator [17].
Results
In total 2487 patients aged 0–24 years were included in
this study: leukaemia (n = 684), lymphoma (n = 558),
CNS tumours (n = 547), germ cell tumours (n = 364), soft
tissue sarcomas (n = 171) and bone tumours (n = 163). The
total number of treating hospitals for each individual
ranged from 1 to 8 (Interquartile range (1 to 2)). Overall
72% of patients received all their treatment at a PTC, 14%
of patients had some treatment at a PTC (ranging from 20
to 85%) and 13% of patients received no treatment at a
PTC.
The percentage of patients treated at PTC differed by
diagnostic group: between 83 and 87% of patients with
leukaemia, CNS and bone tumours received all treat-
ment at PTC, compared to 73% for soft tissue sarcomas,
59% for lymphoma patients and 40% for germ cell tu-
mours (Table 1). Age was also significantly associated
with level of treatment at PTC: children were more
likely to receive all treatment at PTC, with the percent-
age decreasing with increasing age. Females were more
likely to receive all their care at PTC; this was mainly ex-
plained by differences for germ cell tumours. The per-
centage of patients who received all treatment at PTC
increased from 70% for patients diagnosed between 1998
and 2005 to 75% for those diagnosed between 2006 and
2009 (Table 1).
For all diagnostic groups the percentage of children re-
ceiving all treatments at PTC was greater than TYA
(Fig. 1). For haematological malignancies nearly all chil-
dren (97% for leukaemia and 93% for lymphoma) had all
treatments at PTC compared to around 42–49% of TYA.
Approximately 80% of TYA patients with CNS tumours
and bone tumours received all treatments at PTC, while
this figure was 54% for soft tissue sarcomas and 31% for
germ cell tumours. The percentage of patients receiving
all treatment at PTC increased significantly over time for
patients with leukaemia from 81% for those diagnosed
1998–2005 to 88% for those diagnosed 2006–2009, and
for patients with lymphoma from 56 to 66% (Fig. 2).
Leukaemia patients who received some or none of
their treatment at a PTC had a significantly increased
risk of death in unadjusted analyses (Table 2). After
adjustment for patient case-mix a 73% increased risk
of death remained for those who received no
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treatment at PTC with borderline statistical signifi-
cance; adjusted hazard ratio (HR) =1.73, (95%Confi-
dence Interval (CI) (0.98, 3.04)). Individuals with soft
tissue sarcomas who received some or no treatment
at a PTC had a reduced risk of death compared to
those who received all their treatment at a PTC, an
effect which remained significant after our limited ad-
justment for case-mix; adjusted HR = 0.48 (95%CI
(0.23, 0.99)). For lymphoma, CNS tumours, germ cell
tumours and bone tumours there were no statistically
significant differences in survival between those
receiving different levels of treatment at PTC (Table 2,
Additional file 4: Figure S1). Similar patterns of
results were found when restricted to TYA only
(Additional file 5: Table S4).
Figure 3 shows the predicted survival curves for
TYA leukaemia patients, comparing those who re-
ceived all treatment and no treatment at PTC and
with low (equal to the 25th percentile) and high
(equal to the 75th percentile) white cell counts to re-
flect differences in high and low risk cases. Survival
outcomes were similar for the high risk cases who
received all treatment at PTC to the low risk patients
who received no treatment at PTC.
Other variables included in our survival analyses
support previously demonstrated findings, indicating the
generalisability of our findings. For diagnostic groups
where severity of disease was available (leukaemia, lymph-
oma, CNS tumours and germ cell tumours) the risk of
death increased with increasing stage or grade (Additional
file 6: Table S5). TYA had an increased risk of death com-
pared to children for leukaemia, CNS tumours, soft tissue
sarcomas and germ cell tumours (Additional file 6: Table
S5 and Additional file 7: Table S6). For all diagnostic
groups there were survival differences by diagnostic
subgroup and an increased risk of death for those
where no treatment was recorded and those who re-
lapsed. Over the study period the risk of death de-
creased by 7–10% per year on average for lymphoma
and CNS tumours. Increasing deprivation was signifi-
cantly associated with an increased risk of death for
germ cell tumours only, South Asians had an in-
creased risk of death for lymphoma, and there were
no significant differences in survival by sex.
Table 1 Number and percentage of patients by level of treatment at PTC by patient characteristics
Level of treatment at PTC
All Some None Not known
Characteristic Total n (%) n (%) n (%) n (%) p-value
Diagnostic group
Leukaemia 684 567 (82.9) 63 (9.2) 48 (7.0) 6 (0.9) <0.001
Lymphoma 558 328 (58.8) 92 (16.5) 134 (24.0) 4 (0.7)
CNS tumours 547 478 (87.4) 21 (3.8) 36 (6.6) 12 (2.2)
Germ cell tumours 364 146 (40.1) 134 (36.8) 82 (22.5) 2 (0.5)
Soft tissue sarcomas 171 125 (73.1) 29 (17.0) 15 (8.8) 2 (1.2)
Bone tumours 163 136 (83.4) 17 (10.4) 3 (1.8) 7 (4.3)
Age group
0–4 years 496 460 (92.7) 22 (4.4) 6 (1.2) 8 (1.6) <0.001
5–9 years 371 355 (95.7) 11 (3.0) 2 (0.5) 3 (0.8)
10–14 years 405 371 (91.6) 18 (4.4) 11 (2.7) 5 (1.2)
15–19 years 559 329 (58.9) 115 (20.6) 105 (18.8) 11 (2.0)
20–24 years 655 265 (40.5) 190 (29.0) 194 (29.6) 6 (0.9)
Sex
Males 1538 1055 (68.6) 251 (16.3) 208 (13.5) 24 (1.6) <0.001
Females 949 725 (76.4) 105 (11.1) 110 (11.6) 9 (0.9)
Diagnosis period
1998–2005 1671 1168 (69.9) 254 (15.2) 226 (13.5) 23 (1.4) 0.07
2006–2009 816 612 (75.0) 102 (12.5) 92 (11.3) 10 (1.2)
Total 2487 1780 (71.6) 356 (14.3) 318 (12.8) 33 (1.3)
Footnote: Row percentages, p-value from Chi squared test for difference between groups
Level of treatment at PTC “Some” ranges from 20% to 85% of all treatments received at PTC
Abbreviations: PTC = Principal Treatment Centre, CNS = Central nervous system
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Fig. 2 Level of treatment at PTC by diagnostic group and period of diagnosis, Yorkshire 1998–2009. Footnote: All = patient received all treatment
at PTC. Some = patient received some treatment at PTC. Level of treatment at PTC “Some” ranges from 20 to 85% of all treatments received at
PTC. None = patient received no treatment at PTC. PTC = Principal Treatment Centre
Fig. 1 Level of treatment at PTC by diagnostic group and age group, Yorkshire 1998–2009. Footnote: All = patient received all treatment at PTC.
Some = patient received some treatment at PTC. Level of treatment at PTC “Some” ranges from 20 to 85% of all treatments received at PTC.
None = patient received no treatment at PTC. PTC = Principal Treatment Centre
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Discussion
This study is one of the first studies to evaluate differ-
ences in survival by PCT for children and young people
with cancer since the publication of national policy. We
were able to assess survival outcomes by provision of
care at PTC controlling for patient case-mix. In addition
this is one of the first studies to assess the impact of
PTC on survival outcomes in TYA in the UK.
We found that access to PTC varied by diagnostic
group and age: patients with leukaemia, CNS and bone
tumours were more likely to receive all treatment at
PTC as were young children compared to TYA aged
15–24 years. Patients with germ cell tumours were less
likely to receive treatment at PTC (40% received all
treatments at PTC), with clear differences by gender
reflecting different types of tumours and treatment pat-
terns for these patients [18]. Males with testicular germ
cell tumours may receive surgery at a local hospital and
only some will go on to receive chemotherapy, which is
likely to be given at PTC, while others will be assessed
and put on surveillance at PTC; however we were unable
to assess this from our data.
Between 1998 and 2002 in South East England 87% of
10–14 year olds, 55% of 15–19 year olds and 32% of 20–
24 year olds were treated at a either a paediatric cancer
centre or teenage cancer unit [19]. Details were not
available by diagnostic group and findings were based on
first treating hospital only. This compared with our data
indicating 92% of 10–14 year olds, 59% of 15–19 year
olds and 41% of 20–24 year olds received all treatment
at PTC in our study, which included patients diagnosed
after implementation of the IOG. National data for Eng-
land for diagnoses between 2001 and 2006 found that
only 33% of 15–24 year olds received treatment at a
TYA age-specialist centre and this was highest for bone
tumours [7]. We also found that for TYA, patients with
bone and CNS tumours had the highest proportions re-
ceiving all treatment at PTC.
Significant differences in survival outcomes were only
evident for leukaemia and soft tissue sarcomas although
with differing directions of association. For all other
diagnostic groups we did not find an association be-
tween place of treatment and survival.
Leukaemia patients receiving all treatment at PTC had
better outcomes than those who had some or no treat-
ment at PTC. This difference was only partially ex-
plained by patient case-mix. For TYA, predicted survival
outcomes were similar for high risk patients receiving all
Table 2 Five-year survival (%) and hazard ratios (HR) by level treatment at PTC and diagnostic group
5 year survival Unadjusted Adjusteda
Diagnostic group Level of treatment at PTC % Survival 95% CI HR 95%CI HR 95%CI
Leukaemia All 81 (78, 84) 1 - 1 -
Some 57 (44, 68) 2.34 (1.54, 3.56) 1.61 (0.97, 2.67)
None 56 (41, 69) 2.66 (1.68, 4.20) 1.73 (0.98, 3.04)
Lymphoma All 89 (85, 92) 1 - 1 -
Some 84 (74, 90) 1.45 (0.84, 2.51) 1.51 (0.78, 2.92)
None 89 (82, 93) 0.98 (0.56, 1.70) 1.12 (0.54, 2.35)
CNS tumours All 71 (67, 75) 1 - 1 -
Some 76 (52, 89) 0.6 (0.25, 1.48) 0.48 (0.19, 1.20)
None 72 (55, 84) 0.98 (0.54, 1.75) 0.66 (0.34, 1.29)
Germ cell tumours All 91 (85, 95) 1 - 1 -
Some 94 (88, 97) 0.76 (0.34, 1.70) 1.24 (0.42, 3.65)
None 95 (88, 98) 0.62 (0.22, 1.17) 1.83 (0.50, 6.76)
Soft tissue sarcomas All 54 (45, 63) 1 - 1 -
Some & None 75 (59, 85) 0.44 (0.23, 0.83) 0.48 (0.23, 0.99)
Bone tumours All 56 (47, 64) 1 - 1 -
Some & None 60 (36, 78) 0.98 (0.49, 1.97) 0.91 (0.43, 1.88)
Footnote: aAdjusted models from multiple imputation models. Models adjusted for the following
Leukaemia – Diagnostic subgroup, white cell count, age, treatment, relapse, sex, diagnosis year, ethnicity and Townsend area deprivation
Lymphoma – Diagnostic subgroup, stage, age, treatment, relapse, sex, diagnosis year, ethnicity and Townsend area deprivation
CNS tumours – Diagnostic subgroup, grade, age, treatment, relapse, sex, diagnosis year, ethnicity and Townsend area deprivation
Germ cell tumours – Diagnostic subgroup, stage, age, relapse, sex, diagnosis year, ethnicity and Townsend area deprivation (not adjusted for treatment due
to collinearity)
Soft tissue sarcomas – Diagnostic subgroup, age, treatment, relapse, sex, diagnosis year, ethnicity and Townsend area deprivation
Bone tumours – Diagnostic subgroup, primary site, age, treatment, relapse, sex, diagnosis year, ethnicity and Townsend area deprivation
Level of treatment at PTC “Some” ranges from 20% to 85% of all treatments received at PTC
Abbreviations: PTC = Principal Treatment Centre, HR = hazard ratio, CI = confidence interval, CNS = Central nervous system
Fairley et al. BMC Cancer  (2017) 17:168 Page 6 of 9
treatment at PTC and low risk patients receiving no
treatment at a PTC suggesting that PTC were achieving
more favourable outcomes for patients with leukaemia
once risk was measured. For childhood leukaemia some
studies have shown that treatment at a high volume
centre or specialised centre improves survival outcomes
[4, 20–23] while some have shown no differences in sur-
vival by place of care, [24] including one study focusing
on 15–29 year olds with acute leukaemia [25]. Many of
these studies included patients diagnosed many years be-
fore recent UK policy regarding specialisation of services
for this age group.
Soft tissue sarcomas patients who received some or
none of their treatment at a PTC had better survival
outcomes than those who had all treatment at PTC after
some adjustment for patient case-mix. The main caveat
associated with this finding is that we were not able to
adjust for stage due to lack of information on this vari-
able. We did however adjust for some other case-mix
factors thus helping to mediate this effect.
Survival from soft tissue sarcoma is one of the lowest of
all diagnostic groups of cancers in children [26] and TYA
[27] and outcomes are worse for TYA compared to chil-
dren [28, 29]. Specialisation of surgical care for soft tissue
sarcomas has improved outcomes for adult patients [30,
31], however little is known about the outcomes for chil-
dren and TYA. Rhabdomyosarcoma patients, aged 0–14
years, diagnosed between 1977 and 1984 and treated at
Paediatric Oncology Centres had better survival outcomes
than those treated elsewhere in Great Britain, however,
this study included children diagnosed many years ago
and only adjusted for age and year of diagnosis [20]. We
found survival was poorer for patients treated wholly at
PTC, most likely due to differences in case-mix with more
complex cases with worse prognosis more likely to be re-
ferred to PTC. Patients not treated at PTC are more likely
to have small tumours completely resected by local sur-
geons following a presentation where a malignant diagno-
sis was unexpected. The group of patients receiving some
or no treatment at PTC was small and these groups had
to be combined in our analysis to retain statistical power.
Replication of these findings in other large studies both re-
gionally and nationally is needed, along with further ana-
lysis by histological subgroup and collection of stage
information to allow for full patient case-mix adjustment.
For paediatric cancers specialised models of care are
already well developed in many countries. The deve-
lopment of TYA specialist cancer care is beginning to
appear in many European countries [32]. In addition to
examining survival outcomes it is also important to
quantify differences in the quality of care and patient ex-
perience. TYA with cancer are a distinct group with
unique needs, both in terms of the cancers diagnosed in
this age group and their psychosocial and developmental
issues faced. In the UK the BRIGHTLIGHT cohort study
has been funded by the National Institute for Health Re-
search to investigate the added value of specialist care
for TYA [33] with results shortly to be published.
Strengths and limitations
The main strengths of this study were the use of high
quality data including detailed information on patient
Fig. 3 Predicted survival for TYA leukaemia patients with different risk and treatment patterns. Footnote: Comparison of predicted survival for
patients with low risk disease (25th percentile value for white cell count) and those with high risk disease (75th percentile value for white cell
count) who received either all treatment at PTC or no treatment at PTC. Abbreviations WCC =white cell count, PTC = Principal Treatment Centre,
TYA = teenagers and young adults, all PTC = patient received all treatment at PTC, no PTC = patient received no treatment at PTC
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case-mix, treatment and stage. We also used information
on all hospitals where patients were treated. Other stud-
ies have used the first treating hospital only and this
does not capture the full patient journey, for example
patients who might have initially been treated in a non-
specialist centre but then due to complications were re-
ferred to a specialist unit.
Limitations were that we did not consider other
models of care such as shared care, where patients are
managed and discussed at PTC multi-disciplinary team
meetings and subsequently treated at local hospitals [2],
perhaps closer to the patients home, as we did not have
this information. Variations in access to PTC may be
due to a lack of appropriate referrals or patient choice
and we were unable to assess this in our study.
Conclusion
Our analysis provides evidence that treatment at PTC im-
prove outcomes for leukaemia patients especially those
with high risk disease. There is variation in access to PTC
for children and young people with cancer, particularly for
TYA. For four of the six diagnostic groups included in our
study there were no differences in survival outcomes by
the amount of treatment at PTC. However, to fully assess
outcomes for soft tissue sarcoma patients further work is
needed to ensure appropriate case-mix adjustment and
replication of these findings at a national level.
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